Avenue Therapeutics, Inc. (ATXI) financial statements (2020 and earlier)

Company profile

Business Address 2 GANSEVOORT STREET
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14322
Cash and cash equivalents9312
Short-term investments5 10
Deferred costs02 
Total current assets:14422
Noncurrent Assets
Other undisclosed assets000
TOTAL ASSETS:14522
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities253
Accounts payable132
Accrued liabilities111
Employee-related liabilities000
Other undisclosed current liabilities000
Total current liabilities:253
Noncurrent Liabilities
Total liabilities:253
Stockholders' equity
Stockholders' equity attributable to parent, including:12(1)19
Common stock000
Additional paid in capital754239
Accumulated deficit(63)(42)(21)
Other undisclosed stockholders' equity attributable to parent  1
Total stockholders' equity:12(1)19
TOTAL LIABILITIES AND EQUITY:14522

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses(25)(22)(10)
Other undisclosed operating loss  (1)
Operating loss:(25)(22)(11)
Nonoperating income000
Investment income, nonoperating000
Other nonoperating income 0 
Interest and debt expense  (0)
Net loss:(24)(22)(12)
Other undisclosed net loss attributable to parent  (1)
Net loss available to common stockholders, diluted:(24)(22)(12)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(24)(22)(12)
Comprehensive loss, net of tax, attributable to parent:(24)(22)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: